Evidence map›Paper›PMID 40029549›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2025

Spatial distribution of tertiary lymphoid structures in the molecular and clinical context of non-small cell lung cancer.

Hedvig Elfving, Hui Yu, Kaleab Kassete Fessehatsion, Hans Brunnström, Johan Botling, Miklos Gulyas, Max Backman, Amanda Lindberg, Carina Strell, Patrick Micke

Abstract read
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Terminally exhausted CD8Frontiers in immunology · 2025
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hedvig ElfvingDepartment of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, 751 85, Sweden. hedvig.elfving@igp.uu.se.
Hui YuDepartment of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, 751 85, Sweden.
Kaleab Kassete FessehatsionDepartment of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, 751 85, Sweden.
Hans BrunnströmDivision of Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
Johan BotlingDepartment of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, 751 85, Sweden.
Miklos GulyasDepartment of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, 751 85, Sweden.
Max BackmanDepartment of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, 751 85, Sweden.
Amanda LindbergDepartment of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, 751 85, Sweden.
Carina StrellDepartment of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, 751 85, Sweden.
Patrick MickeDepartment of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, 751 85, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTertiary lymphoid structures (TLS) are lymphocyte aggregates resembling secondary lymphoid organs and are pivotal in cancer immunity. The ambiguous morphological definition of TLS makes it challenging to ascertain their clinical impact on patient survival and response to immunotherapy.

objectivesThis study aimed to characterize TLS in hematoxylin-eosin tissue sections from lung cancer patients, assessing their occurrence in relation to the local immune environment, mutational background, and patient outcome.

methodsTwo pathologists evaluated one whole tissue section from resection specimens of 680 NSCLC patients. TLS were spatially quantified within the tumor area or periphery and further categorized based on the presence of germinal centers (mature TLS). Metrics were integrated with immune cell counts, genomic and transcriptomic data, and correlated with clinical parameters.

resultsTLS were present in 86% of 536 evaluable cases, predominantly in the tumor periphery, with a median of eight TLS per case. Mature TLS were found in 24% of cases. TLS presence correlated positively with increased plasma cell (CD138+) and lymphocytic cell (CD3+, CD8+, FOXP3+) infiltration. Tumors with higher tumor mutational burden exhibited higher numbers of peripheral TLS. The overall TLS quantity was independently associated with improved patient survival, irrespective of TLS maturation status. This prognostic association held true for peripheral TLS but not for tumor TLS.

conclusionTLS in NSCLC is common and their correlation with a specific immune phenotype suggests biological relevance in the local immune reaction. The prognostic significance of this scoring system on routine hematoxylin-eosin sections has the potential to augment diagnostic algorithms for NSCLC patients.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsTertiary Lymphoid StructuresAgedAged, 80 and overFemaleHumansLymphocytes, Tumor-InfiltratingMaleMiddle AgedMutationPrognosisTumor MicroenvironmentImmune microenvironmentImmunotherapyLymphocytesPrognosisTumor microenvironment

Identifiers

PMID40029549
PMCPMC12119696

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.